# US 2018/0021352 A1 · Implants and methods for treating inflammation-mediated conditions of the eye

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021352 A1
- Document ID: US20180021352A1
- Status: Published application
- Kind: A1
- Application number: 15/722,180
- Filed: 2017-10-02
- Published: 2018-01-25
- Earliest claimed: 2000-07-05
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Vernon G. Wong; Mae W.L. Hu
- Web page: https://patentgrep.com/patent/US20180021352A1

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 5/38: of the suprarenal hormones
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodihle polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.

## Claims

### Claim at position 1

-5. (canceled)

### Claim 6

A method for treating an inflammation-mediated condition of the eye comprising: implanting into the vitreous of an eye in need thereof a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant is produced by an extrusion method, wherein the total weight of the implant is about 500-1000 μg, and wherein the inflammation-mediated condition of the eye is macular edema.

### Claim 7 (depends on 6)

The method of claim 6, wherein the bioerodible polymer is a polylactic acid polyglycolic acid (PLGA) copolymer.

### Claim 8 (depends on 7)

The method of claim 7, wherein the PLGA copolymer is a 50/50 PLGA copolymer.

### Claim 9 (depends on 7)

The method of claim 7, wherein the steroidal anti-inflam agent comprises about 10% to 90% by weight of the implant.

### Claim 10 (depends on 9)

The method of claim 9, wherein the steroidal anti-inflammatory agent comprises about 50% to about 80% by weight of the implant.

### Claim 11 (depends on 10)

The method of claim 10, wherein the steroidal anti-inflammatory agent is dexamethasone.
